Takeda launches Mepact in EU for osteosarcoma
This article was originally published in Scrip
Executive Summary
Takeda Pharmaceuticals Europe has launched its anti-cancer Mepact (mifamurtide) in the EU for the treatment of adjuvant osteosarcoma (bone cancer).